Publication Name	World Journal of Hepatology
Manuscript ID	90058
Country	Egypt

Category	Oncology
Manuscript Type	Editorial
Article Title	Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
Manuscript Source	Invited Manuscript
All Author List	Mohamed Wishahi
Funding Agency and Grant Number
Corresponding Author	Mohamed Wishahi, MD, PhD, Professor, Surgical Oncologist, Department of Urology, Theodor Bilharz Research Institute , Embaba, Giza, Cairo 12411, Egypt. moh.weshahy@gmail.com
Key Words	Programmed cell death protein-ligand 1; Erdafitinib; Liver cancer; Fibroblast growth factor receptor inhibitors; Checkpoint inhibitors; Bladder cancer; Metastases
Core Tip	The promising results of first-line treatment of advanced and metastatic urothelial carcinoma with programmed cell death protein 1 blockades with single or combined agents, indicate a new concept in the treatment of advanced, metastatic, and recurrent hepatic and gastrointestinal carcinomas. Cancer immunotherapy as a first-line treatment will improve overall survival and quality of life. At present, cancer immunotherapy as first-line treatment in invasive carcinomas or as second-line treatment in recurrent or metastatic carcinoma following the standard chemotherapy is applied on a case-by-case basis.
Citation	Wishahi M. Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept. World J Hepatol 2024; 16(4): 490-493

Received	2023-11-21 21:37
Peer-Review Started	2023-11-21 21:39
To Make the First Decision
Return for Revision	2024-01-24 20:44
Revised	2024-02-08 16:40
Second Decision	2024-03-26 01:24
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-03-26 04:26
Articles in Press	2024-03-26 04:26
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-03-18 05:30
Typeset the Manuscript	2024-04-16 01:10

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com